Search results for

The Intellectual Property Office of the Philippines (IPPhil) is inviting comments from the public on its proposed amendments to the rules and regulations governing the proceedings in administrative complaints for violation of intellectual property laws (infringement, unfair competition, etc), as well as other suggestions. The IPPhil's objective is to shorten the time it takes to issue decisions.

Norway’s new Trade Mark Act entered into force on July 1 2010. The new Act mainly represents a modernisation of the old Act and codification of existing case law, but nevertheless introduces a few practically important changes worth mention.

In a recent copyright infringement case (April 2010) in Malaysia [Suit No D5 (IP)-22-1152-2005], the local high court carefully reviewed certain key facts and legal precedents to meticulously analyse and rule on some important aspects of copyright infringement.

Dr Mohan Dewan and Ameet Deshpande of R K Dewan & Co consider jurisdiction in intellectual property law

Vipul N Bhuta and Sudha Jha of Aditya & Associates discuss trends in opposition and recent developments in design registration

Anuradha Salhotra of Lall Lahiri & Salhotra discusses copyright and domain name issues for IT, software and internet businesses

Thanks to recent patent reforms and its pending membership of the Madrid Protocol, India is firmly part of the global IP system. But, as DIPP joint secretary V Bhaskar tells James Nurton, the country remains sceptical of further harmonisation as it seeks to balance IP protection and development

In a recent decision, the Federal Supreme Court has confirmed some important principles that are relevant for both plaintiffs and defendants in trade mark non-use cancellation actions.

AMexican company Hacienda de los Camichines SA failed to obtain a registration for Purple Label in Russia in respect of goods in class 33 (alcoholic beverages).

Article 19, section VII of the Mexican Industrial Property Law establishes, inter alia, that methods of therapeutic treatment applicable to the human body and to animals shall not be considered as inventions; as a result, such methods are expressly excluded from patentability. However, under Mexican law and practice, there is no exclusion of the possibility for patenting a (new or known) substance or compound for any specific use in a method of therapeutic treatment, as long as such use is new and the claims directed to this kind of matter are written under the first medical use format (compound X for use as a medicament and/or in the treatment of condition Y), or under the subsequent medical use format, also named second medical use format or Swiss-type format (the use of a compound X for manufacturing a medicament for treatment of disease Y).